Literature DB >> 439779

Influence of somatostatin on carbohydrate absorption in human small intestine.

G Pott, H Wagner, E Zierden, K H Hilke, H Jansen, K Hengst, U Gerlach.   

Abstract

Oral carbohydrate tolerance tests with xylose, galactose and lactose were performed. After an interval of at least 24 h the same tests were repeated following an i.v. bolus and during infusion of somatostatin. Somatostatin does not influence xylose absorption. However, absorption of galactose and lactose is significantly reduced (p less than 0.01/0.008) during somatostatin infusion. On the other hand, serum levels of galactose remain unchanged despite administration of somatostatin, when galactose is given parenterally. The results support the assumption that the absorption process in small intestine is affected by somatostatin. Possible effects of somatostatin on hormones regulating the intestinal absorption and on energy-depending carrier mechanisms are discussed.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 439779     DOI: 10.1007/bf01476053

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  12 in total

1.  Evidence for the D-cell of the pancreas secreting somatostatin.

Authors:  L Orci; D Baetens; M P Dubois; C Rufener
Journal:  Horm Metab Res       Date:  1975-09       Impact factor: 2.936

2.  [ON THE ABSORPTION OF MONOSACCHARIDES. I. THE EFFECT OF INSULIN ON THE ABSORPTION OF GALACTOSE].

Authors:  K BEYREISS; F MUELLER; E STRACK
Journal:  Z Gesamte Exp Med       Date:  1964-07-14

3.  [On the specificity of galactose dehydrogenase from Pseudomonas saccharophila and its use as an analytical aid].

Authors:  K WALLENFELS; G KURZ
Journal:  Biochem Z       Date:  1962

4.  Inhibition by somatostatin of ACTH secretion in Nelson's syndrome.

Authors:  J B Tyrrell; M Lorenzi; J E Gerich; P H Forsham
Journal:  J Clin Endocrinol Metab       Date:  1975-06       Impact factor: 5.958

5.  Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin, and growth hormone in normal, diabetic, acromegalic, and hypopituitary patients.

Authors:  C H Mortimer; W M Tunbridge; D Carr; L Yeomans; T Lind; D H Coy; S R Bloom; A Kastin; C N Mallinson; G M Besser; A V Schally; R Hall
Journal:  Lancet       Date:  1974-04-20       Impact factor: 79.321

6.  Inhibition of gastrin and gastric-acid secretion by growth-hormone release-inhibiting hormone.

Authors:  S R Bloom; C H Mortimer; M O Thorner; G M Besser; R Hall; A Gomez-Pan; V M Roy; R C Russell; D H Coy; A J Kastin; A V Schally
Journal:  Lancet       Date:  1974-11-09       Impact factor: 79.321

7.  Inhibition of insulin secretion by somatostatin.

Authors:  K G Alberti; N J Christensen; S E Christensen; A P Hansen; J Iversen; K Lundbaek; K Seyer-Hansen; H Orskov
Journal:  Lancet       Date:  1973-12-08       Impact factor: 79.321

8.  Growth-hormone release-inhibiting hormone in gastrointestinal and pancreatic D cells.

Authors:  J M Polak; A G Pearse; L Grimelius; S R Bloom
Journal:  Lancet       Date:  1975-05-31       Impact factor: 79.321

9.  [Inhibition by somatostatin of pancreatic juice and enzyme secretion and gallbladder contraction in man induced by secretin and cholecystokinin-pancreozymin administration (author's transl)].

Authors:  W Creutzfeldt; P G Lankisch; U R Fölsch
Journal:  Dtsch Med Wochenschr       Date:  1975-05-16       Impact factor: 0.628

10.  Influence of somatostatin on carbohydrate disposal and absorption in diabetes mellitus.

Authors:  J Wahren
Journal:  Lancet       Date:  1976-12-04       Impact factor: 79.321

View more
  3 in total

1.  Somatostatin and the intestinal transport of glucose and other nutrients in the anaesthetised rat.

Authors:  C Daumerie; J C Henquin
Journal:  Gut       Date:  1982-02       Impact factor: 23.059

2.  Somatostatin and 3-oxy-methyl-D-glucose (3-OMG) uptake in isolated chicken intestinal epithelial cells.

Authors:  M Abalde; C Taboada; P Fernández
Journal:  Experientia       Date:  1984-08-15

3.  Effect of chronic octreotide treatment on intestinal absorption in patients with acromegaly.

Authors:  P J Ho; L D Boyajy; E Greenstein; A L Barkan
Journal:  Dig Dis Sci       Date:  1993-02       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.